...
首页> 外文期刊>Infection >Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption.
【24h】

Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption.

机译:在抗逆转录病毒治疗中断后,HIV感染者中隐匿性和明显的乙型肝炎(HBV)感染的分子特征,并重新激活HBV。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: Occult HBV infection is characterized by the absence of surface antigenemia and the presence of potentially infectious hepatitis B virus (HBV)-DNA present in liver, serum, or both. Reactivation of chronic HBV infection in the presence of the HBV surface antigen (HBsAg) is a well-known complication in immunocompromised individuals under cytotoxic chemotherapy or in HIV-infected individuals when nucleos(t)ide analogs effective against HIV/HBV are discontinued. However, little is known on the possibility of such a complication in HIV-infected persons with HBV-core antibody (anti-HBc) as the sole serological marker of past HBV infection. CASE PRESENTATION: Here we report the case of one HIV-infected, anti-HBc-positive individual who showed a severe reactivation of HBV after the interruption of antiretroviral therapy (ART). RESULTS: Analysis of the plasma samples revealed HBV-DNaemia, albeit at very low levels in the latent phase, while the HBV-DNA level was highly increased during the overt phase that corresponded to the period of ART interruption, decreasing dramatically after the subsequent introduction of tenofovir-based ART. Molecular analysis of HBV in the two phases showed that overt HBV infection was due to reactivation of the occult HBV rather than to reinfection. CONCLUSIONS: Our case underlines the possibility that occult HBV infection may still have the potential to be severely reactivated in HIV-infected individuals, particularly when antiretroviral treatment is discontinued.
机译:简介:隐匿性HBV感染的特征是肝脏,血清或两者中均不存在表面抗原血症和存在潜在的传染性乙型肝炎病毒(HBV)-DNA。在细胞毒性化学疗法下免疫受损的个体中或在感染抗HIV / HBV的核苷酸类似物被中止时,在存在HBV表面抗原(HBsAg)的情况下重新激活慢性HBV感染是众所周知的并发症。但是,对于感染了HBV核心抗体(抗HBc)作为过去HBV感染的唯一血清学标志的HIV感染者,这种并发症的可能性知之甚少。病例介绍:在这里,我们报道了一名艾滋病毒感染的抗HBc阳性个体,在抗逆转录病毒治疗(ART)中断后显示严重的HBV再次激活。结果:对血浆样品的分析显示,尽管在潜伏期HBV-DNaemia的水平很低,但在显性阶段HBV-DNA的水平却显着升高,这与ART中断期相对应,随后的引入显着降低基于替诺福韦的抗逆转录病毒疗法。对这两个阶段的HBV进行分子分析表明,明显的HBV感染是由于隐匿性HBV的重新激活而不是重新感染引起的。结论:我们的病例强调了隐匿性HBV感染在HIV感染者中仍有可能被重度激活的可能性,特别是在停止抗逆转录病毒治疗时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号